La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Navidea Biopharmaceuticals Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Navidea Biopharmaceuticals.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.7%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Feb 10

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Navidea Biopharmaceuticals n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

OTCPK:NAVB - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2023	0	-9	-10	-10	N/A
6/30/2023	0	-14	-2	-1	N/A
3/31/2023	0	-16	-8	-8	N/A
12/31/2022	0	-17	-9	-9	N/A
9/30/2022	0	-17	-10	-9	N/A
6/30/2022	0	-12	-10	-9	N/A
3/31/2022	0	-12	-10	-10	N/A
12/31/2021	1	-12	-11	-10	N/A
9/30/2021	1	-11	-10	-10	N/A
6/30/2021	1	-12	-11	-11	N/A
3/31/2021	1	-12	-11	-10	N/A
12/31/2020	1	-11	-9	-8	N/A
9/30/2020	1	-11	-9	-8	N/A
6/30/2020	1	-11	-8	-8	N/A
3/31/2020	1	-11	-8	-8	N/A
12/31/2019	1	-11	-9	-9	N/A
9/30/2019	1	-11	-9	-9	N/A
6/30/2019	1	-12	-8	-8	N/A
3/31/2019	1	-12	4	4	N/A
12/31/2018	1	-16	4	4	N/A
9/30/2018	1	-19	4	4	N/A
6/30/2018	1	-17	5	5	N/A
3/31/2018	2	-18	-11	-11	N/A
12/31/2017	2	-14	59	59	N/A
9/30/2017	2	-10	63	63	N/A
6/30/2017	4	-10	N/A	67	N/A
3/31/2017	5	-8	N/A	73	N/A
12/31/2016	5	-7	N/A	4	N/A
9/30/2016	8	-9	N/A	-3	N/A
6/30/2016	10	-15	N/A	-10	N/A
3/31/2016	12	-24	N/A	-17	N/A
12/31/2015	3	-23	N/A	-19	N/A
9/30/2015	11	-32	N/A	-20	N/A
6/30/2015	9	-31	N/A	-22	N/A
3/31/2015	8	-31	N/A	-24	N/A
12/31/2014	2	-30	N/A	-29	N/A
9/30/2014	5	-43	N/A	-35	N/A
6/30/2014	3	-47	N/A	-38	N/A
3/31/2014	2	-47	N/A	-37	N/A
12/31/2013	1	-43	N/A	-36	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de NAVB est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de NAVB devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de NAVB devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de NAVB devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de NAVB devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de NAVB devrait être élevé dans 3 ans

Navidea Biopharmaceuticals Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Forecast to breakeven in 2024

Consensus revenue estimates increase to US$9.39m

Consensus forecasts updated

Analysts lower revenue estimates to US$763.5k

Recent updates

Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

Navidea Biopharmaceuticals, Inc. Announces Board Resignations

Navidea Biopharmaceuticals, Inc. Files Form 15

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023

Navidea Biopharmaceuticals Requests Oral Hearing with NYSE Hearing Panel

NYSE American Determines to Commence Proceedings to Delist the Common Stock of Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. Announces Executive Changes

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Navidea Biopharmaceuticals Proposes Reverse Stock Split, Stock-For-Debt Swap to End Its Threat of De-Listing

New major risk - Shareholder dilution

High number of new and inexperienced directors

Navidea Biopharmaceuticals Receives NYSE American Notice

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

Navidea Biopharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.56 loss per share (vs US$0.40 loss in FY 2021)

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Cancer Immunotherapy Pipeline

Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc. Files Appeal in CRG Case

Navidea Biopharmaceuticals, Inc. Announces 50th Participant Enrolled in the its Phase 3 Trial in Rheumatoid Arthritis

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.081 loss in 3Q 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Navidea Biopharmaceuticals, Inc. Announces Results from the Completed NAV3-31 Phase 2B Clinical Study as Well as the Preliminary Results of Its Ongoing NAV3-32 Phase 2B Study At Annual Meeting of the American College of Rheumatology

Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics Inc. Announces Court Made an Oral Ruling from Bench in Open Court At the Conclusion of the Trial in Case No. 2018-24442-151

Navidea Biopharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $14.2 million.

Second quarter 2022 earnings released: US$0.099 loss per share (vs US$0.092 loss in 2Q 2021)

Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

First quarter 2022 earnings released: US$0.099 loss per share (vs US$0.11 loss in 1Q 2021)

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc. Announces Positive Preliminary Results of its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India

Navidea Biopharmaceuticals Receives Acceptance Letter from Nyse American

Navidea Biopharmaceuticals Announces Executive Changes

Navidea Biopharmaceuticals Announces Receipt of Noncompliance Notice from NYSE American

Forecast to breakeven in 2024

Navidea Biopharmaceuticals, Inc. Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Programram

Navidea Biopharmaceuticals, Inc. Provides Update on Litigation with Capital Royalty Partners II L.P

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.13 loss in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

Independent Director Claudine Bruck has left the company

Independent Chairman of the Board Sarah Rouan has left the company

Consensus revenue estimates increase to US$9.39m

Second quarter 2021 earnings released: US$0.092 loss per share (vs US$0.11 loss in 2Q 2020)

Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

John K. Scott Requests Navidea Biopharmaceuticals to Appoint Two Additional Members to the Board

Consensus forecasts updated

Chief Business Officer has left the company

Full year 2020 earnings released: US$0.48 loss per share (vs US$0.76 loss in FY 2019)

Navidea Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding

Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Navidea Biopharmaceuticals, Inc. Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

New 90-day high: US$2.89

Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

New 90-day low: US$2.16

Revenue and earnings beat expectations

Third quarter 2020 earnings released: US$0.13 loss per share

Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients from Its Ongoing Phase 2B Study in Rheumatoid Arthritis

New 90-day low: US$2.21

New 90-day low: US$2.58

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation At the American College of Rheumatology Annual Meeting

New 90-day low: US$2.64

Analysts lower revenue estimates to US$763.5k

First half earnings released

Navidea Biopharmaceuticals, Inc. announced that it has received $1 million in funding from Jubilant Pharma Limited

New 90-day high - US$4.87